Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Starting HBV Treatment in Pregnancy: Patient and Physician Sharing Session #1

Source: Addressing Misunderstandings in Applying HBV Treatment Guidelines
In episode 1 of this ongoing series, listen to a conversation between Grace LH Wong, MD, and her patient, Ms. Chan, on the shared decision for Ms. Chan to start treatment for hepatitis B infection during her pregnancy.
Grace LH Wong, MD
Released: March 26, 2021

In this episode, Part 1 of an ongoing series of sharing sessions between a physician and patient, Grace LH Wong, MD, and her patient, Ms. Chan, discuss how they collaborated in care to reach a shared decision regarding HBV treatment initiation. The conversation focuses on how Ms. Chan felt about the decision to start therapy during her pregnancy and how Dr. Wong approaches shared decision-making with her patients regarding their HBV management.

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@clinicaloptions.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from:
Gilead Sciences, Inc.

Information on this Educational Activity

Faculty

Grace LH Wong, MD

Professor
Division of Gastroenterology and Hepatology
Department of Medicine and Therapeutics
The Chinese University of Hong Kong
Honorary Consultant
Division of Gastroenterology and Hepatology
Department of Medicine and Therapeutics
Prince of Wales Hospital
Hong Kong

Grace LH Wong, MD, has disclosed that she has received consulting fees from Gilead Sciences and Janssen; fees for research support from AbbVie and Gilead Sciences; and fees for non-CME/CE services from Abbott, AbbVie, Bristol-Myers Squibb, Echosens, Furui, Gilead Sciences, Janssen, and Roche.

Program Medium

This program has been made available online.

Related Content

Anna Christina L. dela Cruz, MD, and Clinical Care Options (CCO): Treating for hepatitis B despite laboratory values in the gray zone

Anna Christina L. dela Cruz, MD Released: July 28, 2021

Dr. Geoffrey Dusheiko, in conversation with Mark, who was diagnosed with hepatitis B after receiving immunomodulatory treatment for rheumatoid arthritis from Clinical Care Options (CCO)

Geoffrey M. Dusheiko, MD, FCP(SA), FRCP Released: July 26, 2021

Robert Gish on cure strategies at EASL 2021: si RNAs, JNJ-3989, AB-729, GSK3228836, VIR-3434, c-PAMs or capsid inhibitors, AB-836, and more from Clinical Care Options (CCO)

Robert G. Gish, MD Released: July 22, 2021

Top EASL 2021 studies from Clinical Care Options (CCO) and Stefan Zeuzem: HBV Cure, HCV point-of-care testing and treatment cascade, utility of SVR4, emerging HDV treatments

Stefan Zeuzem, MD Released: July 22, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue